Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primer choice shapes microbial community interpretation across habitats and informs short-term structured enrichment in environmental and applied systems.

Frontiers in microbiology·2026
Same author

Scalable Flow Reactors for Stable Biofilm Formation and Continuous Whole-Cell Catalysis.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Carrier-Free Enzyme Immobilization for High-Density Catalytic Architectures in Flow Biocatalysis.

JACS Au·2026
Same author

A carbonic anhydrase-based nanogel for cyanobacterial growth enhancement.

Materials today. Bio·2025
Same author

Low-Cost Temperature Sensing Reveals Thermal Signatures of Microbial Activity in Winogradsky Columns.

Sensors (Basel, Switzerland)·2025
Same author

Materials-Based spatiotemporal analysis of microbial responses to glyphosate in Winogradsky columns.

Methods (San Diego, Calif.)·2025
Same journal

Quercetin suppresses TGF-β1-induced proliferation and migration of vascular smooth muscle cells via the Smad2/3/MMP-9 signaling axis.

Biochemical and biophysical research communications·2026
Same journal

Biosynthesis, characterization and biological potential of microbe-mediated silver nanoparticles using thermophilic actinomycetes, Streptomyces nigra.

Biochemical and biophysical research communications·2026
Same journal

COP9 signalosome 8 mediated autophagy drives proliferation, invasion, and metastasis in pancreatic ductal adenocarcinoma.

Biochemical and biophysical research communications·2026
Same journal

Tumor budding in colorectal cancer: partial EMT, microenvironmental remodeling, and metastatic competence.

Biochemical and biophysical research communications·2026
Same journal

Exploring the therapeutic versatility and multitarget pharmacological potential of acyl hydrazone-hydrazide scaffolds.

Biochemical and biophysical research communications·2026
Same journal

The plasma membrane H<sup>+</sup>-ATPase OSA2 negatively regulates salt tolerance in rice seedlings.

Biochemical and biophysical research communications·2026
See all related articles

Related Experiment Video

Updated: Jun 21, 2026

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

Immuno-PCR assays for immunogenicity testing.

Mark Spengler1, Michael Adler, Andreas Jonas

  • 1Chimera Biotec GmbH, D-44227 Dortmund, Germany. spengler@chimera-biotec.com

Biochemical and Biophysical Research Communications
|July 7, 2009
PubMed
Summary
This summary is machine-generated.

Ultra-sensitive immuno-PCR (IPCR) enhances immunogenicity testing for therapeutic proteins. This method significantly increases sensitivity in detecting anti-drug antibodies (ADA) and offers a promising alternative to traditional assays.

More Related Videos

Use of Interferon-&gamma; Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Related Experiment Videos

Last Updated: Jun 21, 2026

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay
06:15

Characterization of Thymus-dependent and Thymus-independent Immunoglobulin Isotype Responses in Mice Using Enzyme-linked Immunosorbent Assay

Published on: September 7, 2018

Use of Interferon-&gamma; Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

Area of Science:

  • Biotechnology
  • Immunology
  • Analytical Chemistry

Background:

  • Therapeutic protein administration can trigger immunogenic responses, leading to anti-drug antibodies (ADA).
  • ADA can neutralize therapeutic effects and cause adverse health events.
  • Current immunogenicity testing methods may lack sufficient sensitivity and robustness.

Purpose of the Study:

  • To evaluate the utility of ultra-sensitive immuno-PCR (IPCR) for immunogenicity testing of therapeutic proteins.
  • To compare the sensitivity and performance of IPCR with established assay formats like ELISA.
  • To assess the applicability of IPCR in both bridging and neutralizing assay formats.

Main Methods:

  • Employment of the immuno-PCR (IPCR) technique in two established assay formats: a bridging assay and a cell-free neutralizing assay.
  • Quantification of anti-drug antibodies (ADA) using IPCR detection.
  • Comparison of IPCR sensitivity and drug tolerance against ELISA in the bridging assay.
  • Assessment of matrix effects and sample dilution strategies.

Main Results:

  • IPCR demonstrated at least a 1000-fold increase in sensitivity compared to ELISA in the bridging assay.
  • The IPCR bridging assay exhibited high drug tolerance and robustness against biological matrix interference, even with simple sample dilution.
  • The cell-free neutralizing IPCR assay also showed high sensitivity in detecting neutralizing antibodies.
  • IPCR assays maintained high performance without significant loss in assay sensitivity.

Conclusions:

  • Immuno-PCR (IPCR) offers significantly enhanced sensitivity for immunogenicity testing of therapeutic proteins.
  • IPCR is a robust and sensitive method suitable for detecting anti-drug antibodies (ADA) in various assay formats.
  • IPCR holds potential to become a standard methodology for comprehensive immunogenicity assessment in biopharmaceutical development.